Goldman initiates a buy rating on this one-time pandemic stock darling, sees more than 50% upside

Share This Post

A number of catalysts could drive gains for Teladoc Health in the coming months, according to Goldman Sachs.

Subscribe The Newsletter

Get updates and learn from the best

More To Explore

Do You Want To Stay Connected?

drop a line and keep in touch